Boosting Local Waste Management: Sumitomo SHI FW and Woima Finland Oy Bring a Scalable, Easy-to-Deploy Power Plant Solution to the Global Waste-to-Energy Market
13.1.2021 09:00:00 EET | Business Wire | Press release
Sumitomo SHI FW (SFW) and WOIMA Finland Oy (WOIMA) have signed an agreement to deliver the modular wasteWOIMA® waste-to-energy plants. SFW becomes a strategic investor in WOIMA, combining SFW’s renowned expertise in power technology, project execution and global reach with WOIMA’s innovative plant design.
The wasteWOIMA® plant is a unique solution for environmental issues of landfilling and growing municipal waste. It fits small and medium-size cities with local waste management and energy generation.
The plant utilizes robust grate combustion technology to safely treat a wide range of solid wastes, complying with the most stringent environmental standards. It serves a waste collection area of 100,000-500,000 people and converts from 30,000 up to 200,000 tons of non-recyclable waste annually into renewable electricity and heating or cooling.
The concept is scalable and allows for fast deployment: it has 1-4 combustion lines and is based on container-size modules. These workshop-fabricated and pre-assembled modules guarantee a high-quality, cost-effective solution with simple delivery and fast construction. Advanced plant automation and standardized maintenance ensure high plant reliability and reduced operating costs.
Tomas Harju-Jeanty, CEO, SFW: “WOIMA provides a solution to tackle the world’s growing waste challenge on a local level. WOIMA’s innovative solutions will become part of our core technology portfolio, and give us a wider ability to serve our existing and new customers as they seek to manage their waste and move away from fossil fuels.”
Henri Kinnunen, CEO, WOIMA Corporation: “Municipal solid waste is an abundant and under-utilized resource everywhere, and we provide a robust solution to manage it. SFW’s global presence and strong track record in the energy sector strengthens our capability to deliver wasteWOIMA® plants worldwide.”
About SFW
SFW is a provider of power, energy storage and environmental technologies and services for the global energy industry. We strive to provide sustainable energy solutions for a wide portfolio of customer needs in power generation, energy storage, and digital services. www.shi-fw.com
About WOIMA
WOIMA develops innovative modular, standardized solutions that enable the utilization of waste streams to their fullest potential, either as raw material or as energy. www.woimacorporation.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005026/en/
Contact information
SFW
Frank Ligthart
+358 40 5619612
frank.ligthart@shi-g.com
WOIMA
Henri Kinnunen
+358 40 835 8974
henri.kinnunen@woimacorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, alongside cognitive and emotional patterns, including getting stuck in negative or repetitive ways of thinking, difficulty shifting perspective or navigating emotions, and feeling disconnected from pleasure or motivation1-8. While TRD originates as MDD, its burden and resistance to standard treatments distinguish it as a more complex condition. Compared to MDD, TRD patients experience almost 3x long
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 13:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these signals to inform where they plan and prioritize media investment. “Marketers shouldn’t have to guess where demand is coming from before they invest,
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 13:00:00 EEST | Press release
QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems
Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership15.9.2026 12:16:00 EEST | Press release
Axo Longevity today announced the close of an oversubscribed $5M seed round to expand its preventive health membership across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910642125/en/ Axo Longevity preventive health membership The round was backed by MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital and NIAN Sports & Entertainment, alongside angel investors including Dr. Jorge Planas of Clinica Planas Barcelona and Daniel Kulle, former President of H&M and former CEO of Forever 21. Developed to help people understand what is happening inside their body before symptoms appear, Axo Longevity moved from build to live operations in just twelve weeks. The platform is expanding globally, now operating in the United Kingdom, Ireland, Spain, Germany, and the Netherlands, as well as in its first Latin American market, Peru. It is supported by more than 1,400 laboratory
Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth15.9.2026 12:00:00 EEST | Press release
Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026. David joins Chiesi following a distinguished international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development. Following a thorough selection process led by the Board of Directors, David will succeed Interim Group CEO Jean-Marc Bellemin, who has successfully led the Group since 15 May 2026, while also continuing in his permanent role as Group CFO. Maria Paola Chiesi, Chiesi Group Chair, commented: “We are delighted to welcome David to Chiesi at a time of strong momentum for the company. Innovati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom